To compare the cost-effectiveness of 2 commonly used asthma controllers, fluticasone and montelukast, in a population of pediatric patients with mild-to-moderate persistent asthma.

A total of 154 patients (aged 6–14 years) who participated in the Pediatric Asthma Controller Trial (PACT) were included in the study.

This study extracted data from the PACT study, a randomized controlled, double-blind, multicenter trial that studied treatment regimens in children with mild-to-moderate persistent asthma. Both effectiveness and cost measures were used to determine a cost-effectiveness analysis of the 2 controller medications: fluticasone (100 μg twice daily) and montelukast (5 mg daily), given for 48 weeks. Effectiveness measures included (1) asthma-control days (ACDs), (2) improvement in forced expiratory volume in 1 second (FEV1), and (3) the number of exacerbations avoided. Cost measures were taken from (1) direct costs from a third-party payer's perspective, including the sum of costs from asthma-related medication, emergency department visits,...

You do not currently have access to this content.